DK3366295T3 - Fremgangsmåder til behandling af filoviridae virusinfektioner - Google Patents

Fremgangsmåder til behandling af filoviridae virusinfektioner Download PDF

Info

Publication number: DK3366295T3
Authority: DK; Denmark
Prior art keywords: philovirida; treating; methods; virus infections; infections
Prior art date: 2014-10-29

Application number

DK18167340.1T

Other languages

English (en)

Inventor

Byoung Kwon Chun

Michael O'neil Hanrahan Clarke

Edward Doerffler

Hon Chung Hui

Robert Jordan

Richard L Mackman

Jay P Parrish

Adrian S Ray

Dustin Siegel

Original Assignee

Gilead Sciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-10-29

Filing date

2015-10-29

Publication date

2020-04-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54557474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3366295(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2015-10-29 Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc

2020-04-06 Application granted granted Critical

2020-04-06 Publication of DK3366295T3 publication Critical patent/DK3366295T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/02—Phosphorylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/18—Acyclic radicals, substituted by carbocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/14—Pyrrolo-pyrimidine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Plural Heterocyclic Compounds (AREA)

DK18167340.1T 2014-10-29 2015-10-29 Fremgangsmåder til behandling af filoviridae virusinfektioner DK3366295T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462072331P	2014-10-29	2014-10-29
US201562105619P	2015-01-20	2015-01-20
EP15797205.0A EP3212174B1 (en)	2014-10-29	2015-10-29	Methods for treating filoviridae virus infections

Publications (1)

Publication Number	Publication Date
DK3366295T3 true DK3366295T3 (da)	2020-04-06

Family

ID=54557474

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK18167340.1T DK3366295T3 (da)	2014-10-29	2015-10-29	Fremgangsmåder til behandling af filoviridae virusinfektioner
DK15797205.0T DK3212174T3 (da)	2014-10-29	2015-10-29	Fremgangsmåder til behandling af filoviridae-virusinfektioner

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK15797205.0T DK3212174T3 (da)	2014-10-29	2015-10-29	Fremgangsmåder til behandling af filoviridae-virusinfektioner

Country Status (45)

Country	Link
US (8)	US11344565B2 (da)
EP (7)	EP3695844B1 (da)
JP (9)	JP6487547B2 (da)
KR (6)	KR102694960B1 (da)
CN (6)	CN118812607A (da)
AR (2)	AR102467A1 (da)
AU (8)	AU2015339222B2 (da)
BR (2)	BR102015027413A2 (da)
CA (3)	CA3184285A1 (da)
CL (2)	CL2017001040A1 (da)
CO (1)	CO2017003960A2 (da)
CR (2)	CR20170165A (da)
CU (2)	CU20170145A7 (da)
CY (2)	CY1120893T1 (da)
DK (2)	DK3366295T3 (da)
DO (1)	DOP2017000103A (da)
EA (2)	EA201790630A1 (da)
EC (2)	ECSP17025261A (da)
ES (5)	ES2785034T3 (da)
HR (1)	HRP20181130T1 (da)
HU (2)	HUE039231T2 (da)
IL (2)	IL251560A0 (da)
LT (2)	LT3366295T (da)
MA (3)	MA52506A (da)
MD (1)	MD20170046A2 (da)
ME (1)	ME03070B (da)
MX (3)	MX378299B (da)
MY (1)	MY195823A (da)
NZ (3)	NZ745328A (da)
PE (2)	PE20180202A1 (da)
PH (2)	PH12017500631B1 (da)
PL (5)	PL3366295T3 (da)
PT (4)	PT3212174T (da)
RS (1)	RS57425B1 (da)
SA (1)	SA517381419B1 (da)
SG (3)	SG10202008772UA (da)
SI (4)	SI3695844T1 (da)
SM (1)	SMT201800381T1 (da)
SV (2)	SV2017005424A (da)
TR (1)	TR201809518T4 (da)
TW (4)	TWI740546B (da)
UA (1)	UA121485C2 (da)
UY (2)	UY36376A (da)
WO (3)	WO2016069825A1 (da)
ZA (1)	ZA201800414B (da)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HRP20130862T1 (hr)	2009-09-21	2013-10-25	Gilead Sciences, Inc.	Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
SI2595980T1 (sl)	2010-07-22	2014-11-28	Gilead Sciences, Inc.	Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
TWI740546B (zh)	2014-10-29	2021-09-21	美商基利科學股份有限公司	製備核糖苷的方法
LT3785717T (lt)	2015-09-16	2022-04-11	Gilead Sciences, Inc.	Coronaviridae infekcijų gydymo būdai
US11617753B2 (en)	2016-11-10	2023-04-04	Oyagen, Inc.	Methods of treating and inhibiting Ebola virus infection
MA46839A (fr) *	2016-11-18	2021-03-24	Neurovive Pharmaceutical Ab	Promédicaments hépatiques d'ionophores de protons mitochondriaux
CN110869028B (zh)	2017-03-14	2023-01-20	吉利德科学公司	治疗猫冠状病毒感染的方法
JP6923112B2 (ja) *	2017-03-31	2021-08-18	国立大学法人北海道大学	フィロウイルスの細胞侵入阻害活性を有するビアリールスルフォンアミド誘導体
CA3178212A1 (en) *	2017-05-01	2018-11-08	Gilead Sciences, Inc.	Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en)	2017-07-11	2024-11-13	Gilead Sciences, Inc.	Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
JP2020534361A (ja)	2017-09-18	2020-11-26	ヤンセン・バイオファーマ・インコーポレイテッド	置換ヌクレオシド、ヌクレオチド、及びそのアナログ
CN109535200A (zh) *	2017-09-21	2019-03-29	杭州和正医药有限公司	一种核苷类似物的磷酰胺酯前药、药物组合物及其应用
CN109748944B (zh) *	2017-11-03	2021-12-10	中国科学院上海药物研究所	5’-脱氧-5’-异丙基取代氨基核苷类化合物、其制备方法和用途
CN109748943A (zh) *	2017-11-03	2019-05-14	中国科学院上海药物研究所	2’-c-甲基取代核苷类化合物及其制备与用途
CN110330540A (zh) *	2019-08-08	2019-10-15	木天(济南)生物科技有限公司	核苷盐及其制备方法
CN110613726B (zh) *	2019-09-25	2020-10-16	广州六顺生物科技股份有限公司	核苷化合物的应用
WO2021095091A1 (ja) *	2019-11-11	2021-05-20	藤本化学製品株式会社	アミノアリール誘導体及びその中間体、並びにそれらの製造方法
CN110776512A (zh) *	2019-11-28	2020-02-11	成都傲飞生物化学品有限责任公司	一种核苷类似物的制备方法
AU2021214911A1 (en)	2020-01-27	2022-07-21	Gilead Sciences, Inc.	Methods for treating SARS CoV-2 infections
WO2021158248A1 (en)	2020-02-04	2021-08-12	Oyagen, Inc.	Method for treating coronavirus infections
CN113214263B (zh) *	2020-02-06	2022-09-30	北京桦冠医药科技有限公司	瑞德西韦关键中间体的一种合成方法
US20210244705A1 (en) *	2020-02-07	2021-08-12	Centre For Digestive Diseases	Therapeutic compositions, products of manufacture and methods for ameliorating or preventing coronavirus infection
CN111205327B (zh) *	2020-02-17	2022-05-31	南京法恩化学有限公司	一种瑞德西韦的制备方法
TWI883391B (zh)	2020-02-18	2025-05-11	美商基利科學股份有限公司	抗病毒化合物
TWI874791B (zh) *	2020-02-18	2025-03-01	美商基利科學股份有限公司	抗病毒化合物
CA3171648A1 (en)	2020-02-18	2021-08-26	Gilead Sciences, Inc.	Antiviral compounds
TWI791193B (zh) *	2020-02-18	2023-02-01	美商基利科學股份有限公司	抗病毒化合物
CN113292565B (zh) *	2020-02-24	2023-01-31	浙江森科建设有限公司	核苷类化合物及其制备方法和应用
CN111205294B (zh) *	2020-02-27	2021-10-01	江苏阿尔法药业股份有限公司	一种瑞德西韦中间体的制备方法
CN111171078B (zh) *	2020-02-27	2022-04-22	江苏阿尔法药业股份有限公司	一种瑞德西韦的合成方法
CN111187269A (zh) *	2020-02-27	2020-05-22	江苏阿尔法药业有限公司	一种瑞德西韦中间体的合成方法
CN111233930B (zh) *	2020-03-04	2022-05-13	江苏阿尔法药业股份有限公司	一种瑞德西韦的制备方法
CN113354699B (zh) *	2020-03-04	2023-07-18	中国科学院上海药物研究所	瑞德西韦的中间体及其制备方法
CN111269248A (zh) *	2020-03-05	2020-06-12	江苏福瑞康泰药业有限公司	一种核苷氨基磷酸酯类药物母液回收的新方法
CN111269263A (zh) *	2020-03-09	2020-06-12	上海龙翔生物医药开发有限公司	一种瑞德西韦侧链中间体及其制备方法
CN113387954B (zh) *	2020-03-11	2024-03-19	上海特化医药科技有限公司	一种瑞德西韦中间体的制备方法
CN111233870A (zh) *	2020-03-11	2020-06-05	中国科学技术大学	用于快速制备瑞德西韦药物中间体的方法
CN111233869B (zh) *	2020-03-12	2022-09-16	杭州新博思生物医药有限公司	用于制备瑞德西韦关键中间体的新化合物及其制备方法
CA3169340A1 (en)	2020-03-12	2021-09-16	Pavel R. Badalov	Methods of preparing 1'-cyano nucleosides
CN113402546A (zh) *	2020-03-17	2021-09-17	浙江四维医药科技有限公司	一种瑞德西韦磷酸中间体尾链动态动力学拆分方法
US20230125415A1 (en)	2020-03-23	2023-04-27	Genentech, Inc.	Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia
WO2021194860A1 (en)	2020-03-23	2021-09-30	Genentech, Inc.	Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
CN111233931B (zh) *	2020-03-26	2022-03-22	宿迁盛基医药科技有限公司	一种瑞德西韦的合成方法
CN111398464B (zh) *	2020-04-02	2022-03-08	广州隽沐生物科技股份有限公司	2-乙基丁基（（全氟苯氧基）（苯氧基）磷酰基）-l-丙氨酸酯的检测方法
CN113493480B (zh) *	2020-04-03	2025-04-15	南京正大天晴制药有限公司	一种瑞德西韦异构体的制备及其分析方法
CN111423443A (zh) *	2020-04-03	2020-07-17	广州科锐特生物科技有限公司	一种4-氨基-7-碘吡咯并[2,1-f][1,2,4]三嗪的制备方法
WO2021207049A1 (en)	2020-04-06	2021-10-14	Gilead Sciences, Inc.	Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
WO2021207386A1 (en) *	2020-04-07	2021-10-14	Biocryst Pharmaceuticals, Inc.	Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections
CN113811309B (zh) *	2020-04-13	2023-05-05	山东华铂凯盛生物科技有限公司	用于治疗病毒感染的聚合物制剂及制备方法和用途
CN111393494A (zh) *	2020-04-17	2020-07-10	广东帕派恩生物科技有限公司	基于核苷酸结构的化合物、制备方法、用途
CN112778310B (zh) *	2020-04-20	2025-05-30	中国科学院上海药物研究所	核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用
JP2023523415A (ja) *	2020-04-21	2023-06-05	リガンド・ファーマシューティカルズ・インコーポレイテッド	ヌクレオチドプロドラッグ化合物
CN111471070B (zh) *	2020-04-26	2022-05-13	江苏阿尔法药业股份有限公司	瑞德西韦的合成方法
CN111454270B (zh) *	2020-04-27	2024-05-14	南通伟顺生物科技有限公司	一种含六元环的核苷类化合物及其制备方法
CN111440176B (zh) *	2020-04-28	2022-04-26	江苏大学	金属配合物促进的瑞德西韦中间体的合成方法
US10988503B1 (en) *	2020-05-06	2021-04-27	Nantong Weishun Biotechnology Co., Ltd	Six-membered ring-containing nucleoside compound and preparation method thereof
CN113637041B (zh) *	2020-05-11	2024-02-27	上海科胜药物研发有限公司	一种核糖核苷的制备方法
RU2740660C1 (ru) *	2020-05-20	2021-01-19	Общество С Ограниченной Ответственностью "Промомед Рус"	Противовирусная композиция
WO2021237109A1 (en)	2020-05-22	2021-11-25	Trailhead Biosystems Inc.	Combination therapy for treatment of viral infections
CN111961057A (zh) *	2020-05-26	2020-11-20	李小冬	一种α构型核苷及其在治疗猫冠状病毒感染的应用
IN202011022634A (da)	2020-05-29	2020-10-09	Jubilant Generics Limited
WO2021240543A1 (en)	2020-05-29	2021-12-02	Jubilant Generics Limited	Transmucosal pharmaceutical compositions of antiviral drugs
CA3179226A1 (en)	2020-05-29	2021-12-02	Tomas Cihlar	Remdesivir treatment methods
CN113754692B (zh) *	2020-06-03	2022-06-10	上海交通大学	瑞德西韦中间体(s,s)-氨基磷酸酯的不对称催化合成方法
CN113754694B (zh) *	2020-06-03	2022-10-25	上海交通大学	一种不对称催化无保护基核苷合成瑞德西韦的方法
CN113754693B (zh) *	2020-06-03	2022-09-09	上海交通大学	一种磷手性核苷衍生物的不对称催化合成方法及催化剂
WO2021257569A1 (en) *	2020-06-15	2021-12-23	Metro International Biotech, Llc	Anti-viral compounds and methods of use
US20230241225A1 (en)	2020-06-15	2023-08-03	Metro International Biotech, Llc	Anti-viral compounds and methods of use
CN111620903A (zh) *	2020-06-17	2020-09-04	安徽贝克联合制药有限公司	C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用
WO2021262715A1 (en) *	2020-06-23	2021-12-30	Anovent Pharmaceutical (U.S.), Llc	Pharmaceutical formulation containing active metabolites of remdesivir or its analog for inhalation
PE20230618A1 (es)	2020-06-24	2023-04-14	Gilead Sciences Inc	Analogos de nucleosido de 1'-ciano y usos de los mismos
CN111732618A (zh) *	2020-07-03	2020-10-02	镇江巨杰新材料技术研发中心(有限合伙)	瑞德西韦关键片段的合成方法
CN111961079A (zh) *	2020-07-17	2020-11-20	南京正济医药研究有限公司	一种瑞德西韦有关物质及其制备方法和应用
BR112023001129A2 (pt)	2020-07-24	2023-02-14	Univ California	Pró-fármacos antivirais, formulações farmacêuticas e métodos
LT4192839T (lt)	2020-08-06	2025-11-25		Remdesiviro tarpiniai junginiai
CN113004330A (zh) *	2020-08-22	2021-06-22	齐鲁制药有限公司	一种高纯度瑞德西韦的制备方法
MX2023002233A (es)	2020-08-24	2023-03-15	Gilead Sciences Inc	Compuestos fosfolipidos y usos de estos.
DK4204421T3 (da)	2020-08-27	2024-05-27	Gilead Sciences Inc	Forbindelser og fremgangsmåder til behandling af virale infektioner
CN114105989A (zh) *	2020-08-31	2022-03-01	中国科学院大连化学物理研究所	一种碘代吡咯并三嗪胺类化合物的制备方法和应用
WO2022060412A1 (en)	2020-09-17	2022-03-24	Genentech, Inc.	Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
CN112321642A (zh) *	2020-09-28	2021-02-05	南京正济医药研究有限公司	一种瑞德西韦有关物质及其制备方法和用途
WO2022074630A1 (en) *	2020-10-09	2022-04-14	Auxilla Pharmaceuticals And Research Llp	Liquid oral suspension of favipiravir
CN112194661B (zh) *	2020-10-22	2021-06-08	威海同丰海洋生物科技有限公司	一种4-氨基-7-碘吡咯并[2,l-f][l,2,4]三嗪的制备方法
US20230312584A1 (en) *	2020-10-26	2023-10-05	Vigonvita Life Sciences Co., Ltd.	Salt of nucleoside analog, and crystal form, pharmaceutical composition and use thereof
CN114507256B (zh) *	2020-11-16	2025-02-28	上海医药集团股份有限公司	一种瑞德西韦工艺手性异构体、其制备方法及其应用
RU2756921C1 (ru) *	2020-11-20	2021-10-07	Общество С Ограниченной Ответственностью "Технология Лекарств"	Способ получения ремдесивира и фосфорамидаты
BR112023009875A2 (pt)	2020-11-23	2024-02-06	Genentech Inc	Métodos para tratar um indivíduo com uma infecção por sars-cov-2, para reduzir a ligação de sars-cov-2 a uma célula, para diminuir a infecção por sars-cov-2 e para identificar um modulador, métodos de profilaxia, moduladores isolados, usos e antagonistas
CN112358513A (zh) *	2020-12-02	2021-02-12	上海朴颐化学科技有限公司	一种利用连续流反应器制备瑞德西韦中间体的方法
CN114621229B (zh) *	2020-12-11	2024-07-02	嘉兴金派特生物科技有限公司	治疗或预防猫传染性腹膜炎的化合物或组合物
CN114644666A (zh) *	2020-12-18	2022-06-21	上海特化医药科技有限公司	5’-核苷前药的制备方法及中间体
CN114685511A (zh) *	2020-12-25	2022-07-01	上海科胜药物研发有限公司	一种瑞德西韦中间体的纯化方法
CN114685558A (zh) *	2020-12-28	2022-07-01	尚科生物医药（上海）有限公司	一种瑞德西韦中间体的制备方法
CN113754665B (zh) *	2020-12-30	2022-08-19	南方科技大学	一种核苷类化合物的制备方法
CN117777141A (zh) *	2020-12-30	2024-03-29	南方科技大学	一种抗病毒感染的核苷类化合物及其用途
US11998562B2 (en)	2021-01-25	2024-06-04	University Of South Florida	Ophthalmological formulations for the prevention of a coronavirus infection
WO2022166581A1 (zh) *	2021-02-07	2022-08-11	石家庄迪斯凯威医药科技有限公司	一种核苷酸衍生物及其药物组合物和用途
CN117157081A (zh) *	2021-02-19	2023-12-01	南京赛弗斯医药科技有限公司	一种具有抗肿瘤活性的核苷酸衍生物及其药物组合物和用途
CN112979736B (zh) *	2021-03-04	2022-03-25	南京欧信医药技术有限公司	一种瑞德西韦的制备方法
CN115109077A (zh) *	2021-03-18	2022-09-27	上海医药集团股份有限公司	瑞德西韦中间体的制备方法
CN117120444A (zh)	2021-04-16	2023-11-24	吉利德科学公司	使用酰胺制备卡巴核苷的方法
EP4323361A1 (en)	2021-04-16	2024-02-21	Gilead Sciences, Inc.	Methods of preparing carbanucleosides using amides
WO2022251318A1 (en)	2021-05-26	2022-12-01	Gilead Sciences, Inc.	Phospholipid formulations of 1'-cyano substituted carba-nucleoside analogs
CN113683640B (zh) *	2021-08-10	2025-01-14	浙江华海药业股份有限公司	一种丁基瑞德西韦的制备方法
US12116380B2 (en)	2021-08-18	2024-10-15	Gilead Sciences, Inc.	Phospholipid compounds and methods of making and using the same
AU2022331233A1 (en)	2021-08-20	2024-02-29	Shionogi & Co., Ltd.	Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action
CN113999237B (zh) *	2021-10-29	2023-08-08	润佳（苏州）医药科技有限公司	一种核苷类前药及其用途
KR102675967B1 (ko)	2021-11-02	2024-06-17	충남대학교산학협력단	렘데시비르를 함유하는 나노지질담체, 이의 제조방법 및 이를 포함하는 약학적 조성물
CN114409655A (zh) *	2022-01-26	2022-04-29	郑州大学	3′,4′-不饱和核糖c-核苷类似物及其制备方法
TWI867455B (zh)	2022-03-02	2024-12-21	美商基利科學股份有限公司	用於治療病毒感染的化合物及方法
CN115028672A (zh) *	2022-06-14	2022-09-09	南京正济医药研究有限公司	瑞德西韦中间体晶体及其制备方法
CN116874491A (zh) *	2022-07-12	2023-10-13	深圳安泰维生物医药有限公司	一种n-保护的吡咯并三嗪碳苷类化合物及其制备方法
US11655255B2 (en)	2022-10-17	2023-05-23	Sph No.1 Biochemical & Pharmaceutical Co., Ltd.	Method for catalytic asymmetric synthesis of phosphorus-stereogenic (P-stereogenic) nucleoside derivative and catalyst used therein
CN120265297A (zh)	2022-11-18	2025-07-04	吉利德科学公司	治疗痘病毒感染的方法
CN115737675B (zh) *	2022-11-28	2024-03-08	安徽农业大学	氧化型硒代硫酸钠的制备及其在治疗冠状病毒感染中的应用
CN115947759A (zh) *	2022-12-13	2023-04-11	安徽大学	一种治疗新冠药物瑞德西韦的制备方法
CN116332996B (zh) *	2023-05-04	2025-04-01	南京颐媛生物医学研究院有限公司	L-呋喃核糖型抗冠状病毒化合物及其制备方法和应用
CN116284135B (zh) *	2023-05-04	2025-03-21	南京颐媛生物医学研究院有限公司	抗冠状病毒核苷类化合物的制备方法及其应用
HUP2300153A1 (hu)	2023-05-09	2024-11-28	Rotachrom Tech Zrt	Eljárás remdesivir foszfor sztereoizomereinek elválasztására akirális folyadék-folyadék kromatográfiával
CN116554176A (zh) *	2023-05-11	2023-08-08	南京正济医药研究有限公司	一种核苷类化合物的制备方法
CN117126199B (zh) *	2023-05-17	2024-12-06	江西师范大学	一种氟代瑞德西韦合成方法
CN117343114A (zh) *	2023-09-22	2024-01-05	山东大学	一种高立体选择性的α-木糖吡喃糖苷键构建方法
TW202517647A (zh)	2023-09-28	2025-05-01	美商基利科學股份有限公司	用於治療病毒感染的化合物及方法
CN117800872A (zh) *	2023-12-25	2024-04-02	海门瑞一医药科技有限公司	一种4-羟基丁腈的合成方法
US12357577B1 (en)	2024-02-02	2025-07-15	Gilead Sciences, Inc.	Pharmaceutical formulations and uses thereof

Family Cites Families (155)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816570A (en)	1982-11-30	1989-03-28	The Board Of Regents Of The University Of Texas System	Biologically reversible phosphate and phosphonate protective groups
US4968788A (en)	1986-04-04	1990-11-06	Board Of Regents, The University Of Texas System	Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (en)	1990-06-13	1995-12-20	GLAZIER, Arnold	Phosphorous produgs
EP0481214B1 (en)	1990-09-14	1998-06-24	Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic	Prodrugs of phosphonates
JPH1017629A (ja)	1996-07-04	1998-01-20	Kayaku Akzo Kk	ハードコート用樹脂組成物及びその硬化方法
US6887707B2 (en)	1996-10-28	2005-05-03	University Of Washington	Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA
CA2322051A1 (en)	1998-03-03	1999-09-10	Novo Nordisk A/S	New salt forms of (2e)- 5-amino-5- methylhex-2- enoic acid n-methyl-n-((1r)-1-(n- methyl-n-((1r)-1-(methylcarbamoyl)-2- phenylethyl)carbamoyl)-2- (2-naphthyl)ethyl)amide
US6312662B1 (en)	1998-03-06	2001-11-06	Metabasis Therapeutics, Inc.	Prodrugs phosphorus-containing compounds
US6475985B1 (en)	1998-03-27	2002-11-05	Regents Of The University Of Minnesota	Nucleosides with antiviral and anticancer activity
EP1121361B1 (en)	1998-10-16	2007-08-29	Merck Sharp & Dohme Limited	Pyrazolo-triazine derivatives as ligands for gaba receptors
DE19912636A1 (de)	1999-03-20	2000-09-21	Aventis Cropscience Gmbh	Bicyclische Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Herbizide und pharmazeutische Mittel
AU3418800A (en) *	1999-03-24	2000-10-09	Exiqon A/S	Improved synthesis of (2.2.1)bicyclo nucleosides
WO2000075157A1 (en) *	1999-06-03	2000-12-14	Abbott Laboratories	Oligonucleotide synthesis with lewis acids as activators
AUPQ105499A0 (en)	1999-06-18	1999-07-08	Biota Scientific Management Pty Ltd	Antiviral agents
WO2001019375A1 (en)	1999-09-15	2001-03-22	Biocryst Pharmaceuticals, Inc.	Inhibiting t-cell proliferation
EP1225899A2 (en)	1999-11-04	2002-07-31	Virochem Pharma Inc.	Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
EP1296690A2 (en)	2000-02-18	2003-04-02	Shire Biochem Inc.	METHOD FOR THE TREATMENT OR PREVENTION OF i FLAVIVIRUS /i INFECTIONS USING NUCLEOSIDE ANALOGUES
MY164523A (en)	2000-05-23	2017-12-29	Univ Degli Studi Cagliari	Methods and compositions for treating hepatitis c virus
PL359169A1 (en)	2000-05-26	2004-08-23	Idenix (Cayman) Limited	Methods and compositions for treating flaviviruses and pestiviruses
DK1301519T4 (da)	2000-07-21	2021-12-20	Gilead Sciences Inc	Prodrugs af phosphonatnukleotidanaloger og fremgangsmåder til udvælgelse og fremstilling heraf
US20030008841A1 (en)	2000-08-30	2003-01-09	Rene Devos	Anti-HCV nucleoside derivatives
BR0114837A (pt)	2000-10-18	2006-05-09	Pharmasset Ltd	nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
AUPR213700A0 (en)	2000-12-18	2001-01-25	Biota Scientific Management Pty Ltd	Antiviral agents
EP1539188B1 (en)	2001-01-22	2015-01-07	Merck Sharp & Dohme Corp.	Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
DE10145223A1 (de)	2001-09-13	2003-04-03	Basf Ag	Verfahren zur Herstellung von meso-Zeaxanthin
WO2003026675A1 (en)	2001-09-28	2003-04-03	Idenix (Cayman) Limited	Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
AT410792B (de)	2001-12-28	2003-07-25	Dsm Fine Chem Austria Gmbh	Verfahren zur herstellung von geschützten, enantiomeren-angereicherten cyanhydrinen durch in-situ-derivatisierung
US20040023901A1 (en)	2002-02-28	2004-02-05	Cook Phillip D.	Nucleoside 5'-monophosphate mimics and their prodrugs
EP1485395A4 (en)	2002-02-28	2011-04-13	Biota Scient Management	NUCLEOTIDE MIMETICS AND PRODRUGS THEREOF
US20040138170A1 (en)	2002-03-06	2004-07-15	Montgomery John A.	Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
GB0210124D0 (en)	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
GB0210127D0 (en)	2002-05-02	2002-06-12	Merck Sharp & Dohme	Therapeutic agents
US20040063658A1 (en)	2002-05-06	2004-04-01	Roberts Christopher Don	Nucleoside derivatives for treating hepatitis C virus infection
US20050250728A1 (en)	2002-05-23	2005-11-10	Shanta Bantia	Enhancing the efficacy of reverse transcriptase and dna polymerase inhibitors (nucleoside analogs) using pnp inhibitors and/or 2'-deoxyguanosine and/or prodrug thereof
DK1576138T3 (da)	2002-11-15	2017-05-01	Idenix Pharmaceuticals Llc	2'-methylnukleosider i kombination med interferon og flaviviridae-mutation
EA014685B1 (ru)	2003-04-25	2010-12-30	Джилид Сайэнс, Инк.	Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
JP5030587B2 (ja)	2003-06-26	2012-09-19	バイオトロン・リミテッド	抗ウイルスアシルグアニジン化合物および方法
GB0317009D0 (en)	2003-07-21	2003-08-27	Univ Cardiff	Chemical compounds
EP1658302B1 (en)	2003-07-25	2010-08-25	IDENIX Pharmaceuticals, Inc.	Purine nucleoside analogues for treating diseases caused by flaviviridae including hepatitis c
RU2006109491A (ru)	2003-08-27	2006-08-10	Байота, Инк. (Au)	Новые трициклические нуклеозиды или нуклеотиды в качестве терапевтических средств
JP2005187428A (ja) *	2003-12-26	2005-07-14	Univ Of Tokyo	抗ｍｇｌ抗体によるフィロウイルス治療薬
JP2005185235A (ja) *	2003-12-26	2005-07-14	Univ Of Tokyo	ウイルス感染に対する感受性診断のための方法およびキット。
WO2005092877A1 (de)	2004-03-16	2005-10-06	Boehringer Ingelheim International Gmbh	Glucopyranosyl-substituierte benzol-derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2005123087A2 (en)	2004-06-15	2005-12-29	Merck & Co., Inc.	C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7560434B2 (en)	2004-06-22	2009-07-14	Biocryst Pharmaceuticals, Inc.	AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
PT3109244T (pt)	2004-09-14	2019-06-04	Gilead Pharmasset Llc	¿preparação de ribofuranosil pirimidinas e purinas 2¿-fluoro-2¿-alquil substituídas ou outras opcionalmente substituídas e os seus derivados
AU2005317081A1 (en)	2004-10-21	2006-06-22	Merck & Co., Inc.	Fluorinated pyrrolo[2,3-d]pyrimidine nucleosides for the treatment of RNA-dependent RNA viral infection
CN101043893A (zh)	2004-10-21	2007-09-26	默克公司	治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
CN101166750A (zh)	2004-10-29	2008-04-23	拜奥克里斯特制药公司	治疗用呋喃并嘧啶类化合物和噻吩并嘧啶类化合物
EP1828216B1 (en)	2004-12-16	2008-09-10	Boehringer Ingelheim International GmbH	Glucopyranosyl-substituted benzene derivatives, medicaments containing such compounds, their use and process for their manufacture
JP2008532950A (ja)	2005-03-08	2008-08-21	バイオタサイエンティフィックマネージメントピーティーワイリミテッド	治療薬としての二環式ヌクレオシドおよび二環式ヌクレオチド
US7514410B2 (en)	2005-03-29	2009-04-07	Biocryst Pharmaceuticals, Inc.	Hepatitis C therapies
AR056327A1 (es)	2005-04-25	2007-10-03	Genelabs Tech Inc	Compuestos de nucleosidos para el tratamiento de infecciones virales
WO2006121820A1 (en)	2005-05-05	2006-11-16	Valeant Research & Development	Phosphoramidate prodrugs for treatment of viral infection
WO2007027248A2 (en)	2005-05-16	2007-03-08	Valeant Research & Development	3', 5' - cyclic nucleoside analogues for treatment of hcv
NZ596107A (en)	2005-06-24	2013-09-27	Biotron Ltd	Antiviral compounds and methods
CN101321775B (zh)	2005-10-03	2012-05-23	大学健康网络	用于治疗疟疾的odcase抑制剂
JP5116687B2 (ja)	2005-11-02	2013-01-09	バイエル・ファルマ・アクチェンゲゼルシャフト	がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
BRPI0619120B1 (pt)	2005-12-01	2023-10-10	Basilea Pharmaceutica Ag	Processo para a fabricação de derivados de epóxi triazol
US8143393B2 (en)	2005-12-02	2012-03-27	Bayer Healthcare Llc	Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
PE20070855A1 (es)	2005-12-02	2007-10-14	Bayer Pharmaceuticals Corp	Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
EP1971331A2 (en)	2005-12-09	2008-09-24	Basilea Pharmaceutica AG	4-oxo-(iso)tretinoin for the topical treatment of severe dermatological disorders
BRPI0619563A2 (pt)	2005-12-09	2011-10-04	Pharmasset Inc	nucleosìdeos antivirais
WO2007097991A2 (en)	2006-02-16	2007-08-30	Pharmasset, Inc.	Methods and kits for dosing of antiviral agents
DE102006015378A1 (de)	2006-04-03	2007-10-04	Ludwig-Maximilians-Universität München	Verfahren zur Synthese von Organoelementverbindungen
CL2007001427A1 (es)	2006-05-22	2008-05-16	Novartis Ag	Sal de maleato de 5-amino-3-(2',3'-di-o-acetil-beta-d-ribofuranosil)-3h-tiazolo[4,5-d]pirimidin-2-ona; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de una infeccion po
WO2008005542A2 (en)	2006-07-07	2008-01-10	Gilead Sciences, Inc.,	Antiviral phosphinate compounds
US20080161324A1 (en)	2006-09-14	2008-07-03	Johansen Lisa M	Compositions and methods for treatment of viral diseases
CL2007003187A1 (es) *	2006-11-06	2008-03-07	Boehringer Ingelheim Int	Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
AU2007338899A1 (en)	2006-12-20	2008-07-03	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Nucleoside cyclic phosphoramidates for the treatment of RNA-dependent RNA viral infection
US20080261913A1 (en)	2006-12-28	2008-10-23	Idenix Pharmaceuticals, Inc.	Compounds and pharmaceutical compositions for the treatment of liver disorders
AU2007342367B2 (en)	2007-01-05	2012-12-06	Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A.	Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
ES2390188T3 (es)	2007-01-12	2012-11-07	Biocryst Pharmaceuticals, Inc.	Análogos de nucleósidos antivirales
CN101730699A (zh)	2007-03-21	2010-06-09	百时美施贵宝公司	可用于治疗增殖性、变应性、自身免疫性和炎症性疾病的稠合杂环化合物
US7964580B2 (en)	2007-03-30	2011-06-21	Pharmasset, Inc.	Nucleoside phosphoramidate prodrugs
DK2155758T3 (da)	2007-05-10	2012-11-05	Biocryst Pharm Inc	Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer
CN100532388C (zh)	2007-07-16	2009-08-26	郑州大学	2’-氟-4’-取代-核苷类似物、其制备方法及应用
WO2009018609A1 (en)	2007-08-03	2009-02-12	Biotrom Limited	Hepatitis c antiviral compositions and methods
KR101502533B1 (ko)	2007-11-22	2015-03-13	에스케이케미칼주식회사	우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법
TW200942243A (en)	2008-03-05	2009-10-16	Biocryst Pharm Inc	Antiviral therapeutic agents
US8227431B2 (en)	2008-03-17	2012-07-24	Hetero Drugs Limited	Nucleoside derivatives
US7863291B2 (en)	2008-04-23	2011-01-04	Bristol-Myers Squibb Company	Quinuclidine compounds as alpha-7 nicotinic acetylcholine receptor ligands
AP3237A (en) *	2008-04-23	2015-04-30	Gilead Sciences Inc	1'-Substituted carba-nucleoside analogs for antiviral treatment
WO2010036407A2 (en)	2008-05-15	2010-04-01	Biocryst Pharmaceuticals, Inc.	Antiviral nucleoside analogs
WO2010002877A2 (en)	2008-07-03	2010-01-07	Biota Scientific Management	Bycyclic nucleosides and nucleotides as therapeutic agents
BRPI1013643A2 (pt)	2009-02-10	2016-04-19	Gilead Sciences Inc	análogos de carba-nucleosídeo para tratamento antiviral
AR075584A1 (es)	2009-02-27	2011-04-20	Intermune Inc	COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
CA2755642A1 (en)	2009-03-20	2010-09-23	Alios Biopharma, Inc.	Substituted nucleoside and nucleotide analogs
MX2011009928A (es)	2009-03-24	2012-03-16	Biocryst Pharm Inc	Sales farmaceuticas utiles de 7[(3r, 4r)-3-hidroxi-4-hidroximetil- pirrolidin-1-ilmetil]-3,5-dihidro-pirrol[3,2-d]pirimidin-4-ona.
TWI598358B (zh)	2009-05-20	2017-09-11	基利法瑪席特有限責任公司	核苷磷醯胺
WO2011011303A1 (en)	2009-07-21	2011-01-27	Gilead Sciences, Inc.	Inhibitors of flaviviridae viruses
HRP20130862T1 (hr) *	2009-09-21	2013-10-25	Gilead Sciences, Inc.	Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida
US8455451B2 (en)	2009-09-21	2013-06-04	Gilead Sciences, Inc.	2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
US7973013B2 (en)	2009-09-21	2011-07-05	Gilead Sciences, Inc.	2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
NZ599402A (en)	2009-09-21	2014-02-28	Gilead Sciences Inc	2’ -fluoro substituted carba-nucleoside analogs for antiviral treatment
AU2010338011B2 (en)	2009-12-28	2015-04-02	Development Center For Biotechnology	Novel pyrimidine compounds as mTOR and P13K inhibitors
PT3290428T (pt)	2010-03-31	2021-12-27	Gilead Pharmasset Llc	Comprimido compreendendo 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2h)-il)¿4¿fluoro¿3¿hidroxi¿4¿metiltetrahidrofuran¿2¿il)metoxi) (fenoxi)fosforil)amino)propanoato de (s)- isopropil cristalino
EP2609923B1 (en)	2010-03-31	2017-05-24	Gilead Pharmasset LLC	Process for the crystallisation of (s)-isopropyl 2-(((s)-(perfluorophenoxy)(phenoxy)phosphoryl)amino)propanoate
TW201201815A (en)	2010-05-28	2012-01-16	Gilead Sciences Inc	1'-substituted-carba-nucleoside prodrugs for antiviral treatment
US9090642B2 (en)	2010-07-19	2015-07-28	Gilead Sciences, Inc.	Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
SI2595980T1 (sl)	2010-07-22	2014-11-28	Gilead Sciences, Inc.	Postopki in sestavki za zdravljenje paramyxoviridae virusnih infekcij
TW201305185A (zh) *	2010-09-13	2013-02-01	Gilead Sciences Inc	用於抗病毒治療之２’－氟取代之碳－核苷類似物
PE20230684A1 (es)	2010-09-20	2023-04-21	Gilead Sciences Inc	Analogos de carba-nucleosidos sustituidos con 2'-fluoro como inhibidores de la arn polimerasa
CN103209987B (zh)	2010-09-22	2017-06-06	艾丽奥斯生物制药有限公司	取代的核苷酸类似物
JP5902698B2 (ja)	2010-10-15	2016-04-13	バイオクライストファーマシューティカルズ，インコーポレイテッド	ポリメラーゼの阻害のための方法および組成物
WO2012075140A1 (en)	2010-11-30	2012-06-07	Pharmasset, Inc.	Compounds
AU2011349844B2 (en)	2010-12-20	2017-06-01	Gilead Sciences, Inc.	Combinations for treating HCV
KR20140019832A (ko)	2011-04-13	2014-02-17	길리애드 사이언시즈, 인코포레이티드	항바이러스 치료를 위한 1''-치환 피리미딘 ν-뉴클레오사이드 유사체
KR20130138840A (ko)	2011-04-13	2013-12-19	머크 샤프 앤드 돔 코포레이션	2''-치환된 뉴클레오시드 유도체 및 바이러스성 질환의 치료를 위한 그의 사용 방법
ES2639122T3 (es)	2011-05-13	2017-10-25	Zoetis Services Llc	Composiciones inmunogénicas de glucoproteína G de virus Hendra y Nipah
WO2013039861A2 (en) *	2011-09-12	2013-03-21	modeRNA Therapeutics	Engineered nucleic acids and methods of use thereof
UA116087C2 (uk)	2011-09-16	2018-02-12	Гіліад Фармассет Елелсі	Композиція для лікування вірусу гепатиту c
US8889159B2 (en)	2011-11-29	2014-11-18	Gilead Pharmasset Llc	Compositions and methods for treating hepatitis C virus
WO2013084165A1 (en) *	2011-12-05	2013-06-13	Medivir Ab	Hcv polymerase inhibitors
US20130143835A1 (en) *	2011-12-05	2013-06-06	Medivir Ab	HCV Polymerase Inhibitors
HK1203075A1 (en) *	2011-12-22	2015-10-16	艾丽奥斯生物制药有限公司	Substituted phosphorothioate nucleotide analogs
SG11201407674TA (en)	2012-05-22	2014-12-30	Idenix Pharmaceuticals Inc	D-amino acid compounds for liver disease
EP2890704B1 (en)	2012-08-31	2018-02-28	Novartis AG	2'-ethynyl nucleoside derivatives for treatment of viral infections
WO2014037480A1 (en)	2012-09-10	2014-03-13	F. Hoffmann-La Roche Ag	6-amino acid heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
WO2014042433A2 (en) *	2012-09-14	2014-03-20	Kainos Medicine, Inc.	Compounds and compositions for modulating adenosine a3 receptor activity
EP3251674A3 (en)	2012-11-16	2018-02-21	BioCryst Pharmaceuticals, Inc.	Antiviral azasugar-containing nucleosides
US9732111B2 (en)	2012-11-19	2017-08-15	Merck Sharp & Dohme Corp.	2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP3912984A1 (en) *	2012-12-21	2021-11-24	Janssen BioPharma, Inc.	4'-fluoro-nucleosides, 4'-fluoro-nucleotides and analogs thereof for the treatment of hcv
WO2014116755A1 (en)	2013-01-22	2014-07-31	Massachusetts Institute Of Technology	Uses of dihydro bases
US10034893B2 (en)	2013-02-01	2018-07-31	Enanta Pharmaceuticals, Inc.	5, 6-D2 uridine nucleoside/tide derivatives
RU2015148010A (ru)	2013-04-12	2017-05-15	Ачиллион Фармасютикалз, Инк.	Высокоактивное производное нуклеозида для лечения hcv
US9542154B2 (en)	2013-06-25	2017-01-10	Intel Corporation	Fused multiply add operations using bit masks
UA117375C2 (uk) *	2013-09-04	2018-07-25	Медівір Аб	Інгібітори полімерази hcv
MX377523B (es)	2013-09-11	2025-03-10	Inst Nat Sante Rech Med	Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
UA119050C2 (uk) *	2013-11-11	2019-04-25	Ґілеад Саєнсиз, Інк.	ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
EA201691261A1 (ru)	2014-01-30	2016-11-30	Ф. Хоффманн-Ля Рош Аг	Новые дигидрохинолизиноны для лечения и профилактики инфекции, вызванной вирусом гепатита b
CA2935811C (en)	2014-03-07	2018-09-18	F. Hoffmann-La Roche Ag	6-fused heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
RU2016146365A (ru)	2014-05-13	2018-06-19	Ф. Хоффманн-Ля Рош Аг	Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b
US9616076B2 (en) *	2014-06-02	2017-04-11	The Board Of Regents Of The University Of Texas Systems	Methods for treating viral infections using hydrogen sulfide donors
US9504701B2 (en)	2014-06-02	2016-11-29	The Board Of Regents Of The University Of Texas System	Methods for treating viral infections using hydrogen sulfide donors
WO2016012470A1 (en)	2014-07-25	2016-01-28	F. Hoffmann-La Roche Ag	New amorphous and crystalline forms of (3s)-4-[[(4r)-4-(2-chloro-4-fluoro-phenyl)-5-methoxycarbonyl-2-thiazol-2-yl-1, 4-dihydropyrimidin-6-yl]methyl]morpholine-3-carboxylic acid
EP3180319B1 (en)	2014-08-14	2018-10-03	F.Hoffmann-La Roche Ag	Novel pyridazones and triazinones for the treatment and prophylaxis of hepatitis b virus infection
TWI740546B (zh)	2014-10-29	2021-09-21	美商基利科學股份有限公司	製備核糖苷的方法
US9637485B2 (en)	2014-11-03	2017-05-02	Hoffmann-La Roche Inc.	6,7-dihydrobenzo[a]quinolizin-2-one derivatives for the treatment and prophylaxis of hepatitis B virus infection
US9676793B2 (en)	2014-12-23	2017-06-13	Hoffmann-Laroche Inc.	Co-crystals of 5-amino-2-oxothiazolo[4,5-d]pyrimidin-3(2H)-yl-5-hydroxymethyl tetrahydrofuran-3-yl acetate and methods for preparing and using the same
AR103222A1 (es)	2014-12-23	2017-04-26	Hoffmann La Roche	Procedimiento para la preparación de análogos de 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidina
WO2016107832A1 (en)	2014-12-30	2016-07-07	F. Hoffmann-La Roche Ag	Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
EP3240913A1 (en)	2014-12-31	2017-11-08	F. Hoffmann-La Roche AG	A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr
MA41338B1 (fr)	2015-01-16	2019-07-31	Hoffmann La Roche	Composés de pyrazine pour le traitement de maladies infectieuses
CN107208102B (zh)	2015-01-27	2021-07-06	豪夫迈·罗氏有限公司	重组hbv cccdna、其产生方法及其用途
EP3256471B1 (en)	2015-02-11	2018-12-12	F. Hoffmann-La Roche AG	Novel 2-oxo-6,7-dihydrobenzo[a]quinolizine-3-carboxylic acid derivatives for the treatment and prophylaxis of hepatitis b virus infection
LT3785717T (lt)	2015-09-16	2022-04-11	Gilead Sciences, Inc.	Coronaviridae infekcijų gydymo būdai
WO2017184668A1 (en)	2016-04-20	2017-10-26	Gilead Sciences, Inc.	Methods for treating flaviviridae virus infections
ES2910136T3 (es)	2017-02-08	2022-05-11	Biotron Ltd	Métodos de tratamiento de la gripe
CN110869028B (zh)	2017-03-14	2023-01-20	吉利德科学公司	治疗猫冠状病毒感染的方法
CA3178212A1 (en)	2017-05-01	2018-11-08	Gilead Sciences, Inc.	Crystalline forms of (s)-2-ethylbutyl 2-(((s)-(((2r,3s,4r,5r)-5-(4-aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
EP3651734B1 (en)	2017-07-11	2024-11-13	Gilead Sciences, Inc.	Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections
CN111265532A (zh)	2020-01-21	2020-06-12	中国人民解放军军事科学院军事医学研究院	取代氨基丙酸酯类化合物在治疗2019-nCoV感染中的应用
AU2021214911A1 (en)	2020-01-27	2022-07-21	Gilead Sciences, Inc.	Methods for treating SARS CoV-2 infections
CA3169340A1 (en) *	2020-03-12	2021-09-16	Pavel R. Badalov	Methods of preparing 1'-cyano nucleosides

2015
- 2015-10-27 TW TW109120726A patent/TWI740546B/zh active
- 2015-10-27 TW TW104135247A patent/TWI687432B/zh active
- 2015-10-27 TW TW104135248A patent/TWI698444B/zh active
- 2015-10-27 TW TW109109475A patent/TWI767201B/zh active
- 2015-10-28 BR BR102015027413A patent/BR102015027413A2/pt not_active Application Discontinuation
- 2015-10-29 CU CUP2017000145A patent/CU20170145A7/xx unknown
- 2015-10-29 PL PL18167340T patent/PL3366295T3/pl unknown
- 2015-10-29 SM SM20180381T patent/SMT201800381T1/it unknown
- 2015-10-29 WO PCT/US2015/057932 patent/WO2016069825A1/en not_active Ceased
- 2015-10-29 EP EP20152978.1A patent/EP3695844B1/en active Active
- 2015-10-29 ES ES18167340T patent/ES2785034T3/es active Active
- 2015-10-29 CN CN202410806375.0A patent/CN118812607A/zh active Pending
- 2015-10-29 EP EP18167340.1A patent/EP3366295B1/en active Active
- 2015-10-29 CA CA3184285A patent/CA3184285A1/en active Pending
- 2015-10-29 AR ARP150103505A patent/AR102467A1/es not_active Application Discontinuation
- 2015-10-29 HU HUE15797205A patent/HUE039231T2/hu unknown
- 2015-10-29 LT LTEP18167340.1T patent/LT3366295T/lt unknown
- 2015-10-29 SG SG10202008772UA patent/SG10202008772UA/en unknown
- 2015-10-29 MA MA052506A patent/MA52506A/fr unknown
- 2015-10-29 WO PCT/US2015/057933 patent/WO2016069826A1/en not_active Ceased
- 2015-10-29 MX MX2017005250A patent/MX378299B/es unknown
- 2015-10-29 SI SI201532063T patent/SI3695844T1/sl unknown
- 2015-10-29 SG SG11201702903TA patent/SG11201702903TA/en unknown
- 2015-10-29 US US14/926,063 patent/US11344565B2/en active Active
- 2015-10-29 KR KR1020177014043A patent/KR102694960B1/ko active Active
- 2015-10-29 EP EP15801008.2A patent/EP3212175B1/en active Active
- 2015-10-29 HR HRP20181130TT patent/HRP20181130T1/hr unknown
- 2015-10-29 NZ NZ745328A patent/NZ745328A/en unknown
- 2015-10-29 CN CN202111041161.1A patent/CN113620992B/zh active Active
- 2015-10-29 WO PCT/US2015/057934 patent/WO2016069827A1/en not_active Ceased
- 2015-10-29 ES ES15797205.0T patent/ES2674806T3/es active Active
- 2015-10-29 CN CN202111480947.3A patent/CN114191438A/zh active Pending
- 2015-10-29 EP EP25164258.3A patent/EP4591935A2/en active Pending
- 2015-10-29 KR KR1020177014110A patent/KR102337664B1/ko active Active
- 2015-10-29 RS RS20180822A patent/RS57425B1/sr unknown
- 2015-10-29 SI SI201531150T patent/SI3366295T1/sl unknown
- 2015-10-29 PE PE2017002319A patent/PE20180202A1/es unknown
- 2015-10-29 SI SI201531764T patent/SI3212175T1/sl unknown
- 2015-10-29 PL PL15797205T patent/PL3212174T3/pl unknown
- 2015-10-29 NZ NZ730803A patent/NZ730803A/en unknown
- 2015-10-29 PT PT157972050T patent/PT3212174T/pt unknown
- 2015-10-29 EP EP25167754.8A patent/EP4588928A3/en active Pending
- 2015-10-29 ME MEP-2018-183A patent/ME03070B/me unknown
- 2015-10-29 UY UY0001036376A patent/UY36376A/es unknown
- 2015-10-29 DK DK18167340.1T patent/DK3366295T3/da active
- 2015-10-29 EP EP21209687.9A patent/EP4036099B1/en active Active
- 2015-10-29 MD MDA20170046A patent/MD20170046A2/ro not_active Application Discontinuation
- 2015-10-29 US US14/926,062 patent/US9724360B2/en active Active
- 2015-10-29 PL PL21209687.9T patent/PL4036099T3/pl unknown
- 2015-10-29 PL PL15801008T patent/PL3212175T3/pl unknown
- 2015-10-29 CU CUP2017000056A patent/CU20170056A7/es unknown
- 2015-10-29 AU AU2015339222A patent/AU2015339222B2/en active Active
- 2015-10-29 KR KR1020247026762A patent/KR20240125990A/ko active Pending
- 2015-10-29 EA EA201790630A patent/EA201790630A1/ru unknown
- 2015-10-29 UA UAA201703584A patent/UA121485C2/uk unknown
- 2015-10-29 TR TR2018/09518T patent/TR201809518T4/tr unknown
- 2015-10-29 PH PH1/2017/500631A patent/PH12017500631B1/en unknown
- 2015-10-29 CN CN202110878274.0A patent/CN113549120B/zh active Active
- 2015-10-29 MY MYPI2017701244A patent/MY195823A/en unknown
- 2015-10-29 KR KR1020217039965A patent/KR102453808B1/ko active Active
- 2015-10-29 CR CR20170165A patent/CR20170165A/es unknown
- 2015-10-29 CR CR20170483A patent/CR20170483A/es unknown
- 2015-10-29 ES ES15801008T patent/ES2904298T3/es active Active
- 2015-10-29 KR KR1020227034888A patent/KR20220140656A/ko not_active Withdrawn
- 2015-10-29 SG SG11201702904RA patent/SG11201702904RA/en unknown
- 2015-10-29 LT LTEP15797205.0T patent/LT3212174T/lt unknown
- 2015-10-29 AU AU2015339223A patent/AU2015339223B2/en active Active
- 2015-10-29 NZ NZ730809A patent/NZ730809A/en unknown
- 2015-10-29 CA CA2963907A patent/CA2963907C/en active Active
- 2015-10-29 MX MX2017005252A patent/MX2017005252A/es unknown
- 2015-10-29 SI SI201530258T patent/SI3212174T1/en unknown
- 2015-10-29 ES ES21209687T patent/ES3020561T3/es active Active
- 2015-10-29 PE PE2017000745A patent/PE20171439A1/es unknown
- 2015-10-29 CN CN201580059611.6A patent/CN107073005B/zh active Active
- 2015-10-29 PT PT158010082T patent/PT3212175T/pt unknown
- 2015-10-29 PT PT181673401T patent/PT3366295T/pt unknown
- 2015-10-29 PT PT201529781T patent/PT3695844T/pt unknown
- 2015-10-29 PL PL20152978.1T patent/PL3695844T3/pl unknown
- 2015-10-29 EP EP15797205.0A patent/EP3212174B1/en active Active
- 2015-10-29 MA MA040867A patent/MA40867A/fr unknown
- 2015-10-29 MA MA040872A patent/MA40872A/fr unknown
- 2015-10-29 AR ARP150103506A patent/AR102468A1/es unknown
- 2015-10-29 DK DK15797205.0T patent/DK3212174T3/da active
- 2015-10-29 JP JP2017520934A patent/JP6487547B2/ja active Active
- 2015-10-29 EA EA201790597A patent/EA032239B1/ru unknown
- 2015-10-29 JP JP2017520938A patent/JP6220484B1/ja active Active
- 2015-10-29 BR BR112017007636A patent/BR112017007636A2/pt not_active Application Discontinuation
- 2015-10-29 CA CA2963832A patent/CA2963832C/en active Active
- 2015-10-29 HU HUE18167340A patent/HUE049192T2/hu unknown
- 2015-10-29 CN CN201580059613.5A patent/CN107074902A/zh active Pending
- 2015-10-29 KR KR1020177014042A patent/KR101822348B1/ko active Active
- 2015-10-29 ES ES20152978T patent/ES3026734T3/es active Active
2016
- 2016-08-24 US US15/246,240 patent/US9949994B2/en active Active
2017
- 2017-04-04 IL IL251560A patent/IL251560A0/en unknown
- 2017-04-12 IL IL251707A patent/IL251707B/en active IP Right Grant
- 2017-04-21 MX MX2020012560A patent/MX2020012560A/es unknown
- 2017-04-24 CO CONC2017/0003960A patent/CO2017003960A2/es unknown
- 2017-04-24 EC ECIEPI201725261A patent/ECSP17025261A/es unknown
- 2017-04-24 DO DO2017000103A patent/DOP2017000103A/es unknown
- 2017-04-24 SV SV2017005424A patent/SV2017005424A/es unknown
- 2017-04-26 CL CL2017001040A patent/CL2017001040A1/es unknown
- 2017-04-27 SA SA517381419A patent/SA517381419B1/ar unknown
- 2017-06-06 JP JP2017111470A patent/JP6757294B2/ja active Active
- 2017-10-24 CL CL2017002693A patent/CL2017002693A1/es unknown
- 2017-10-30 EC ECIEPI201772474A patent/ECSP17072474A/es unknown
- 2017-11-01 UY UY0001037464A patent/UY37464A/es not_active Application Discontinuation
- 2017-11-03 SV SV2017005561A patent/SV2017005561A/es unknown
2018
- 2018-01-19 ZA ZA201800414A patent/ZA201800414B/en unknown
- 2018-02-22 US US15/902,690 patent/US10251898B2/en active Active
- 2018-07-06 JP JP2018129006A patent/JP6671424B2/ja active Active
- 2018-08-10 CY CY20181100844T patent/CY1120893T1/el unknown
- 2018-10-23 AU AU2018253483A patent/AU2018253483B2/en active Active
2019
- 2019-01-07 JP JP2019000664A patent/JP2019048901A/ja not_active Withdrawn
- 2019-02-12 US US16/274,049 patent/US10695357B2/en active Active
- 2019-02-22 AU AU2019201232A patent/AU2019201232B2/en active Active
- 2019-11-22 US US16/692,966 patent/US20200197422A1/en not_active Abandoned
2020
- 2020-02-14 JP JP2020023613A patent/JP2020090536A/ja not_active Withdrawn
- 2020-03-06 JP JP2020038878A patent/JP7158428B2/ja active Active
- 2020-04-14 CY CY20201100351T patent/CY1122946T1/el unknown
- 2020-05-22 US US16/881,419 patent/US11266666B2/en active Active
- 2020-06-12 AU AU2020203892A patent/AU2020203892A1/en not_active Abandoned
- 2020-07-08 PH PH12020551055A patent/PH12020551055A1/en unknown
2021
- 2021-03-09 AU AU2021201474A patent/AU2021201474B2/en active Active
2022
- 2022-02-07 US US17/665,724 patent/US20220354873A1/en not_active Abandoned
- 2022-02-10 JP JP2022019651A patent/JP2022065066A/ja not_active Withdrawn
- 2022-02-18 JP JP2022024119A patent/JP2022068297A/ja active Pending
- 2022-12-09 AU AU2022283772A patent/AU2022283772A1/en not_active Abandoned
2023
- 2023-05-02 AU AU2023202679A patent/AU2023202679A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DOP2017000103A (es)	2017-05-15
SG11201702903TA (en)	2017-05-30
JP7158428B2 (ja)	2022-10-21
PT3212174T (pt)	2018-06-28
LT3366295T (lt)	2020-04-27
CY1122946T1 (el)	2021-10-29
US11266666B2 (en)	2022-03-08
MD20170046A2 (ro)	2017-10-31
CY1120893T1 (el)	2020-05-29
ES2785034T3 (es)	2020-10-05
JP2020097635A (ja)	2020-06-25
KR20170077167A (ko)	2017-07-05
PL3695844T3 (pl)	2025-07-21
CL2017002693A1 (es)	2018-04-20
JP6220484B1 (ja)	2017-10-25
PE20180202A1 (es)	2018-01-31
PH12017500631A1 (en)	2017-09-25
ES3026734T3 (en)	2025-06-12
AU2022283772A1 (en)	2023-02-02
MA40867A (fr)	2017-09-06
BR112017007636A2 (pt)	2017-12-19
AU2018253483B2 (en)	2020-04-16
US20210052613A1 (en)	2021-02-25
EP4591935A2 (en)	2025-07-30
PH12020551055A1 (en)	2021-07-26
HK1258795A1 (en)	2019-11-22
SI3212174T1 (en)	2018-06-29
EP4036099A1 (en)	2022-08-03
HUE049192T2 (hu)	2020-09-28
AU2023202679A1 (en)	2023-05-18
KR102453808B1 (ko)	2022-10-12
AU2019201232B2 (en)	2020-12-10
CR20170483A (es)	2018-01-22
JP2018172424A (ja)	2018-11-08
KR20210152015A (ko)	2021-12-14
KR20240125990A (ko)	2024-08-20
KR102337664B1 (ko)	2021-12-10
NZ745328A (en)	2023-06-30
BR102015027413A2 (pt)	2016-05-03
JP2022068297A (ja)	2022-05-09
CN113620992A (zh)	2021-11-09
US10695357B2 (en)	2020-06-30
CN114191438A (zh)	2022-03-18
IL251560A0 (en)	2017-05-29
EP3366295A1 (en)	2018-08-29
TW202115098A (zh)	2021-04-16
SV2017005561A (es)	2018-12-05
ES2904298T3 (es)	2022-04-04
AU2015339222B2 (en)	2018-11-22
UY37464A (es)	2019-04-30
US20160122374A1 (en)	2016-05-05
EP3212174A1 (en)	2017-09-06
KR101822348B1 (ko)	2018-01-25
US11344565B2 (en)	2022-05-31
UY36376A (es)	2016-06-01
SMT201800381T1 (it)	2018-09-13
TR201809518T4 (tr)	2018-07-23
US9949994B2 (en)	2018-04-24
ES3020561T3 (en)	2025-05-23
US20190275063A1 (en)	2019-09-12
CA2963832A1 (en)	2016-05-06
AU2015339223A1 (en)	2017-04-27
JP2019048901A (ja)	2019-03-28
MX378299B (es)	2025-03-10
SI3695844T1 (sl)	2025-06-30
ECSP17072474A (es)	2017-12-01
MX2017005250A (es)	2017-07-26
PT3212175T (pt)	2022-01-25
CA2963907A1 (en)	2016-05-06
CN107074902A (zh)	2017-08-18
MA40872A (fr)	2021-05-26
JP2017186358A (ja)	2017-10-12
TW202039526A (zh)	2020-11-01
KR20170066665A (ko)	2017-06-14
CA2963832C (en)	2020-06-16
RS57425B1 (sr)	2018-09-28
MX2017005252A (es)	2017-07-26
SG10202008772UA (en)	2020-10-29
KR102694960B1 (ko)	2024-08-14
JP2017533903A (ja)	2017-11-16
LT3212174T (lt)	2018-07-10
AU2021201474B2 (en)	2023-02-02
TW201629076A (zh)	2016-08-16
CN113620992B (zh)	2024-09-03
EA201790630A1 (ru)	2017-11-30
CL2017001040A1 (es)	2018-01-19
SV2017005424A (es)	2018-07-18
CR20170165A (es)	2017-06-19
MY195823A (en)	2023-02-22
UA121485C2 (uk)	2020-06-10
EP4588928A3 (en)	2025-09-24
HUE039231T2 (hu)	2018-12-28
TWI687432B (zh)	2020-03-11
AU2018253483A1 (en)	2018-11-15
WO2016069825A1 (en)	2016-05-06
JP2022065066A (ja)	2022-04-26
ME03070B (me)	2019-01-20
PL4036099T3 (pl)	2025-06-23
PL3212174T3 (pl)	2018-09-28
SI3212175T1 (sl)	2022-01-31
US20160122356A1 (en)	2016-05-05
PL3366295T3 (pl)	2020-08-24
IL251707A0 (en)	2017-06-29
TWI698444B (zh)	2020-07-11
EP4036099B1 (en)	2025-03-19
US20160361330A1 (en)	2016-12-15
EP3366295B1 (en)	2020-01-22
JP6757294B2 (ja)	2020-09-16
JP6487547B2 (ja)	2019-03-20
PT3366295T (pt)	2020-04-21
TWI740546B (zh)	2021-09-21
US20220354873A1 (en)	2022-11-10
US10251898B2 (en)	2019-04-09
PH12017500631B1 (en)	2024-01-05
ES2674806T3 (es)	2018-07-04
EP3695844B1 (en)	2025-04-02
US20180311263A1 (en)	2018-11-01
CN113549120B (zh)	2025-04-29
CN107073005A (zh)	2017-08-18
EP3212174B1 (en)	2018-05-16
JP2017534614A (ja)	2017-11-24
AU2015339222A1 (en)	2017-04-27
TWI767201B (zh)	2022-06-11
AR102467A1 (es)	2017-03-01
MA52506A (fr)	2021-03-10
PE20171439A1 (es)	2017-09-29
SA517381419B1 (ar)	2022-07-07
EP4588928A2 (en)	2025-07-23
JP6671424B2 (ja)	2020-03-25
WO2016069826A1 (en)	2016-05-06
AU2021201474A1 (en)	2021-03-25
WO2016069827A1 (en)	2016-05-06
EP4036099C0 (en)	2025-03-19
NZ730803A (en)	2018-09-28
ECSP17025261A (es)	2017-05-31
NZ730809A (en)	2018-09-28
PL3212175T3 (pl)	2022-02-28
CN118812607A (zh)	2024-10-22
PT3695844T (pt)	2025-05-29
SI3366295T1 (sl)	2020-06-30
EA032239B1 (ru)	2019-04-30
EP3212175B1 (en)	2021-11-24
DK3212174T3 (da)	2018-08-06
HRP20181130T1 (hr)	2018-09-21
AU2015339223B2 (en)	2018-07-26
KR20220140656A (ko)	2022-10-18
EA201790597A1 (ru)	2017-11-30
CA3184285A1 (en)	2016-05-06
SG11201702904RA (en)	2017-05-30
CO2017003960A2 (es)	2017-07-11
TW201630925A (zh)	2016-09-01
EP3212175A1 (en)	2017-09-06
AU2020203892A1 (en)	2020-07-02
AU2019201232A1 (en)	2019-03-14
JP2020090536A (ja)	2020-06-11
CA2963907C (en)	2023-04-04
CU20170056A7 (es)	2017-07-04
CU20170145A7 (es)	2018-07-05
MX2020012560A (es)	2021-02-09
CN113549120A (zh)	2021-10-26
AR102468A1 (es)	2017-03-01
US9724360B2 (en)	2017-08-08
US20200197422A1 (en)	2020-06-25
IL251707B (en)	2019-12-31
EP3695844A1 (en)	2020-08-19
ZA201800414B (en)	2019-10-30
CN107073005B (zh)	2021-12-24
KR20170067898A (ko)	2017-06-16

Publication	Publication Date	Title
DK3366295T3 (da)	2020-04-06	Fremgangsmåder til behandling af filoviridae virusinfektioner
DK3286311T3 (da)	2021-05-17	Fremgangsmåde til behandling af maligniteter
PL3349758T3 (pl)	2022-09-12	Sposoby leczenia zakażeń wirusami arenaviridae
DK3400291T4 (da)	2024-04-02	Manipuleret virus
DK3851537T3 (da)	2024-03-18	Behandling af hyperbilirubinæmi
DK3110988T3 (da)	2019-07-29	Metoder til behandling af lithiumholdige materialer
DK3186376T3 (da)	2019-05-06	Fremgangsmåder til forbedring af cas9-medieret manipulationseffektivitet
DK3466432T3 (da)	2020-09-28	Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner
DK3099298T3 (da)	2019-05-27	Kombinationsterapier med zidovudin til behandling af mikrobielle infektioner
DK3134084T3 (da)	2021-05-03	Fremgangsmåde til behandling af lungeadenokarcinom
DK3130392T3 (da)	2021-01-18	Virusfjernelsesmembran
PL3386655T3 (pl)	2023-08-21	Sposób przetwarzania odpadów
DK3393468T3 (da)	2022-12-19	Fremgangsmåder til behandling af en immundefektsygdom
DK3307267T3 (da)	2019-07-01	Behandling af multipel sklerose
EP3398042A4 (en)	2019-10-09	REMOVAL OF BACKGROUND
DK3143123T3 (da)	2020-02-10	Mikrorna-induktion af kardiologisk regenerering
DK3373980T3 (da)	2025-06-30	Fremgangsmåder til behandling af muskeldystrofi
DK3209319T3 (da)	2021-10-04	En fremgangsmåde til behandling af svampeinfektioner
DK3848028T5 (da)	2025-01-20	Fremgangsmåder til behandling af øjenlidelser
IL254783A0 (en)	2017-12-31	Anthelmintic combinations and methods of use thereof
DK3855181T3 (da)	2025-02-10	Forbindelser til behandling af lipofuscinrelaterede sygdomme
DK2942098T3 (da)	2019-06-17	Forbedret fremgangsmåde til fjernelse af nitrit
DK3200783T3 (da)	2019-08-05	Behandling af erytromelalgi
DK2965765T3 (da)	2019-07-22	Anvendelse af adelmidrol til behandling af epiteldysfunktioner
DK3359572T3 (da)	2025-01-27	Fremgangsmåde til behandling af multipel sklerose